Drug Trial Radar · NCT03590054
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
Last checked: Nov 19, 2026Latest source record: Mar 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Aug 20, 2018
Primary completion
Nov 30, 2023
Study completion Nov 30, 2023
Sponsor
- Lead sponsor
- Rahul AggarwalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Xynomic Pharmaceuticals, Inc.
- First posted
- Jul 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies the best dose and side effects of abexinostat and how well it works with given together with pembrolizumab in treating participants with microsatellite instability (MSI) solid tumors that have spread to other places in the body. Abexinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving abexinostat and pembrolizumab may work better in treating participants with solid tumors.
Conditions
- Stage III Cutaneous Melanoma
- Stage IV Cutaneous Melanoma
- Locally Advanced Melanoma
- Locally Advanced Solid Neoplasm
- Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Metastatic Urothelial Carcinoma
- Non-Small Cell Lung Carcinoma
- Stage IB Lung Cancer AJCC v7
- Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Stage III Lung Cancer AJCC v8
- Stage III Ureter Cancer AJCC v8
- Stage IIIA Lung Cancer AJCC v8
- Stage IIIB Lung Cancer AJCC v8
- Stage IIIC Lung Cancer AJCC v8
- Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IV Ureter Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8
Interventions
AbexinostatDrug
Given orally (PO) twice a day (BID) days 1-4, 8-11 of every 21 day cycle
PembrolizumabBiological
Given IV on day 1 of every 21 day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximally Tolerated Dose (MTD)Time frame: Up to 21 days
- Objective Response Rate (ORR)Time frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.